Monopar Therapeutics Future Growth
Future criteria checks 0/6
Monopar Therapeutics's earnings are forecast to decline at 18.9% per annum while its annual revenue is expected to grow at 91.7% per year. EPS is expected to grow by 16.9% per annum.
Key information
-18.9%
Earnings growth rate
16.9%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 91.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 22 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -14 | -12 | -10 | 3 |
| 12/31/2025 | N/A | -12 | -11 | -10 | 3 |
| 12/31/2024 | N/A | -7 | -9 | -7 | 3 |
| 9/30/2024 | N/A | -6 | -6 | -6 | N/A |
| 6/30/2024 | N/A | -7 | -7 | -7 | N/A |
| 3/31/2024 | N/A | -8 | -7 | -7 | N/A |
| 12/31/2023 | N/A | -8 | -8 | -8 | N/A |
| 9/30/2023 | N/A | -9 | -8 | -8 | N/A |
| 6/30/2023 | N/A | -10 | -8 | -8 | N/A |
| 3/31/2023 | N/A | -10 | -7 | -7 | N/A |
| 12/31/2022 | N/A | -11 | -7 | -7 | N/A |
| 9/30/2022 | N/A | -10 | -8 | -8 | N/A |
| 6/30/2022 | N/A | -10 | -8 | -8 | N/A |
| 3/31/2022 | N/A | -10 | -8 | -8 | N/A |
| 12/31/2021 | N/A | -9 | -7 | -7 | N/A |
| 9/30/2021 | N/A | -9 | -7 | -7 | N/A |
| 6/30/2021 | N/A | -8 | -6 | -6 | N/A |
| 3/31/2021 | N/A | -7 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -6 | -5 | -5 | N/A |
| 9/30/2020 | N/A | -5 | -4 | -4 | N/A |
| 6/30/2020 | N/A | -4 | -3 | -3 | N/A |
| 3/31/2020 | N/A | -4 | -3 | -3 | N/A |
| 12/31/2019 | N/A | -4 | -3 | -3 | N/A |
| 9/30/2019 | N/A | -4 | -3 | -3 | N/A |
| 6/30/2019 | N/A | -4 | -3 | -3 | N/A |
| 3/31/2019 | N/A | -4 | -3 | -3 | N/A |
| 12/31/2018 | N/A | -3 | -3 | -3 | N/A |
| 9/30/2018 | N/A | -3 | -3 | -3 | N/A |
| 6/30/2018 | N/A | -17 | N/A | -4 | N/A |
| 3/31/2018 | N/A | -17 | N/A | -3 | N/A |
| 12/31/2017 | N/A | -17 | N/A | -3 | N/A |
| 9/30/2017 | N/A | -16 | N/A | -2 | N/A |
| 6/30/2017 | N/A | -1 | N/A | -1 | N/A |
| 3/31/2017 | N/A | -1 | N/A | -1 | N/A |
| 12/31/2016 | N/A | -1 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1IY0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1IY0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1IY0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1IY0 is forecast to have no revenue next year.
High Growth Revenue: 1IY0 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1IY0's Return on Equity is forecast to be high in 3 years time